Standout Papers

Psoriatic arthritis: epidemiology, clinical features, course, and outcome 2004 2026 2011 2018 1.1k
  1. Psoriatic arthritis: epidemiology, clinical features, course, and outcome (2005)
    Dafna D. Gladman, Christian Antoni et al. Annals of the Rheumatic Diseases
  2. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis (2015)
    Philip J. Mease, Iain B. McInnes et al. New England Journal of Medicine
  3. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed (2004)
    L.B.A. van de Putte, Catherine Atkin et al. Annals of the Rheumatic Diseases
  4. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study (2013)
    Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism
  5. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (2017)
    Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases
  6. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial (2021)
    Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases
  7. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis (2023)
    Gerd R Burmester, Stanley Cohen et al. RMD Open

Immediate Impact

8 from Science/Nature 80 standout
Sub-graph 1 of 18

Citing Papers

Rheumatoid arthritis
2023 Standout
Systemic sclerosis
2022 Standout
93 intermediate papers

Works of Peter Nash being referenced

A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
2015
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
2012
and 32 more

Author Peers

Author Last Decade Papers Cites
Peter Nash 7217 5052 3708 342 11.1k
Kimme L Hyrich 7420 3114 3750 312 11.8k
D Alarcón-Segovia 7109 4324 1621 340 12.0k
Gianfranco Ferraccioli 5806 2652 1683 365 11.2k
Bernard Combe 9754 3210 3633 475 13.9k
Carlomaurizio Montecucco 4959 2238 1861 429 9.7k
Filip De Keyser 5071 3017 1440 236 9.1k
Roberto Caporali 5544 2168 1680 442 10.1k
Tatsuya Atsumi 9186 4140 4881 502 15.0k
A. Zink 7466 2999 3211 236 10.9k
Maxime Dougados 18909 9126 6754 541 23.2k

All Works

Loading papers...

Rankless by CCL
2026